Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma - Related Studies

Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

This study is currently recruiting participants.

Study NCT00128102. Last updated on November 18, 2008. Information provided by Merck

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Mesothelioma
		Lung Cancer

2	Additional conditions recognized in this trial
		Lung Neoplasms

3	More general conditions related to this trial
		Adenoma
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplasms, Mesothelial
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Thoracic Neoplasms

4	Interventions listed in this trial
		Placebo (unspecified)

5	Additional drug interventions recognized in this trial
		Suberoylanilide hydroxamic acid

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Anticarcinogenic Agents
		Antineoplastic Agents
		Antirheumatic Agents
		Central Nervous System Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protective Agents
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Merck